A Multicenter, Randomized, Double-blind, Placebo-controlled Trial on the Treatment of Hypertensive Intracerebral Hemorrhage With Naoxuekang Dropping Pills
A phase 2 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 1950 participants.
Also called NCT07200921
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 1,950 participants
- Registry
-
NCT07200921
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- China
- Registry status
- Not yet recruiting
Technical summary
Registry record NCT07200921. Randomized; quadruple masking; primary purpose treatment. Start 2025-10-10 (anticipated); primary completion 2028-11-30 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Multicenter, Randomized, Double-blind, Placebo-controlled Trial on the Treatment of Hypertensive Intracerebral Hemorrhage With Naoxuekang Dropping Pills
- Acronym
- TCM-ICH
- Condition
- Hypertensive Intracerebral Hemorrhage
- Condition
- Cerebral Small Vessel Diseases
- Intervention (Drug)
- Naoxuekang Dropping Pills
- Intervention (Drug)
- Naoxuekang Matching Placebo
- Lead sponsor
- Beijing Tiantan Hospital
- Collaborator
- The Affiliated Hospital of Qingdao University
- Collaborator
- Beijing Kangerfu Pharmaceutical Company Limited
Record details
- Record id
cardio:ct-nct07200921- Content hash
dd7083b0f5e091a57eca1496f180ae86a8f2668772daaa64267fd2a67964791c